Black Diamond Therapeutics soars on positive data from early-stage lung cancer study
27/06/2023 17:34
** Shares of precision oncology medicine co Black Diamond
Therapeutics Inc BDTX.O up more than double at $4.2 - hit near
one-and-half-year high
** Co reports initial data from dose escalation portion of
early-stage study showing anti-tumor activity of its lead
candidate BDTX-1535 in patients with a type of lung cancer
urn:newsml:reuters.com:*:nGNX6vM2sK
** Adds that update on dose escalation data in patients with
brain tumor anticipated in Q4 2023
** Wedbush raises rating to "outperform" from "neutral" and
target price to $10 from $3
** Shares more than double in 2023, including Tuesday's
gains
(Reporting by Vedant Vinayak Vichare in Bengaluru)
((vedant.vinayakvichare@thomsonreuters.com))